AVITA Medical, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $RCEL in the last 7 days.
No SEC Form 4 filings for $RCEL in the last 30 days.
See all $RCEL insider activity →TD Cowen raised its price target on Avita Medical (RCEL) to $14.00 from $12.00, citing confidence in PermeaDerm's commercial potential. The stock is up 185% YTD. Avita reported Q2 revenue of $21.7M, beating estimates, and BTIG upgraded its rating to Buy with a $11.00 target. PermeaDerm trial data showed economic benefits over allograft.
Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
Avita Medical (NASDAQ:RCEL) said it targets cash-flow breakeven in Q4 2025 as revenue grows. CEO Vance said the company can expand without adding sales reps for at least 18 months and cited data for RECELL, including a 36% shorter length of stay vs split-thickness grafting. Reimbursement issues are easing, with a simplified Medicare code planned for Jan. 1, 2027.
Recent RCEL coverage spans earnings, market movers and technology.
Positive trial data and analyst upgrades suggest near-term upside for RCEL.
Cost and workflow advantages versus allograft, alongside comparable clinical outcomes, can improve adoption odds and valuation expectations.
Management is signaling a specific breakeven timeline and cost discipline, with reimbursement normalization and underpenetration as key growth levers.
Guidance raise plus improving cash burn reduces near-term financing risk, while CMS reimbursement changes and RECELL adoption drive forward demand expectations.
Guidance and margin/cash-flow trajectory suggest improving fundamentals, with near-term focus on execution toward Q4 2026 breakeven.
alphai scores every news story that mentions RCEL with an AI model for sentiment and relevance, and aggregates insider trades from AVITA Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TD Cowen raised its price target on Avita Medical (RCEL) to $14.00 from $12.00, citing confidence in PermeaDerm's commercial potential. The stock is up 185% YTD. Avita reported Q2 revenue of $21.7M, beating estimates, and BTIG upgraded its rating to Buy with a $11.00 target. PermeaDerm trial data showed economic benefits over allograft.
2 min readAmylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
4 min readAvita Medical (NASDAQ:RCEL) said it targets cash-flow breakeven in Q4 2025 as revenue grows. CEO Vance said the company can expand without adding sales reps for at least 18 months and cited data for RECELL, including a 36% shorter length of stay vs split-thickness grafting. Reimbursement issues are easing, with a simplified Medicare code planned for Jan. 1, 2027.
4 min readAvita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.
7 min readAVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.
7 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 5, 2026, the Company and Stedical Scientific, Inc. (“Stedical”) entered into a Global Amendment of their existing distribution agreement and manufacturing agreement (the “Global Amendment”). Under the terms of the Gl
6 min readAvita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.
4 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care comp
6 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readWoody Joseph Fralin purchased 5,200 shares of AVITA Medical, Inc. (RCEL) at $4.00 on 2026-06-09.
2 min read
